PELP-1 promotes adverse endocrine therapy response in ER plus breast cancer

被引：0
|
作者：
Rees, Michael [1 ]
Smith, Chris [2 ]
Barrett-Lee, Peter [1 ]
Hiscox, Stephen [2 ]
机构：
[1] Velindre Canc Ctr, Cardiff, S Glam, Wales
[2] Cardiff Univ, Cardiff, S Glam, Wales
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2884
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2884
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PELP-1 regulates adverse endocrine responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer
    Rees, M.
    Smith, C.
    Hiscox, S.
    Barrett-Lee, P.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S121 - S122
  • [2] Endocrine agents promote adverse responses in ER plus breast cancer cells through a mechanism involving PELP1
    Rees, Michael
    Smith, Chris
    Barrett-Lee, Peter
    Hiscox, Steve
    CANCER RESEARCH, 2020, 80 (04)
  • [3] Notch signaling in ER plus breast cancer in response to endocrine therapy agents
    Singleton, Ciera S.
    Miele, Lucio
    Crabtree, Judy S.
    CANCER RESEARCH, 2019, 79 (13)
  • [4] ARID1A promotes endocrine resistance in ER plus breast cancer cells.
    Chabot, Catherine
    Basik, Mark
    CANCER RESEARCH, 2013, 73 (08)
  • [5] Semaphorin 7a promotes cell survival and resistance to endocrine therapy in ER plus breast cancer
    Lyons, Traci Renae
    CANCER RESEARCH, 2020, 80 (16)
  • [6] A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER plus Breast Cancer
    Altwegg, Kristin A.
    Viswanadhapalli, Suryavathi
    Mann, Monica
    Chakravarty, Dimple
    Krishnan, Samaya
    Liu, Zexuan
    Liu, Junhao
    Pratap, Uday P.
    Ebrahimi, Behnam
    Sanchez, John R.
    Li, Xiaonan
    Ma, Shihong
    Park, Ben H.
    Santhamma, Bindu
    Chen, Yidong
    Lai, Zhao
    V. Raj, Ganesh
    Yuan, Yaxia
    Zhou, Daohong
    Sareddy, Gangadhara R.
    Tekmal, Rajeshwar R.
    McHardy, Stan
    Huang, Tim H. -M.
    Rao, Manjeet K.
    Vankayalapati, Hariprasad
    Vadlamudi, Ratna K.
    CANCER RESEARCH, 2022, 82 (20) : 3830 - 3844
  • [7] Lessons for ER plus breast cancer from neoadjuvant endocrine therapy trials
    Ellis, Matthew J.
    CLINICAL CANCER RESEARCH, 2018, 24 (01) : 18 - 18
  • [8] PELP1 and AIB1 cooperate to promote breast cancer progression in ER plus breast cancer models.
    Truong, Thu H.
    Hu, Hsiangyu
    Ostrander, Julie H.
    Lange, Carol A.
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 40 - 41
  • [9] PELP1-TFAP2C crosstalk promotes endocrine resistance in breast cancer cells
    Liu, Junhao
    Viswanadhapalli, Suryavathi
    Li, Mengxing
    Pratap, Uday P.
    Tang, Weiwei
    Liu, Zexuan
    Luo, Yiliao
    Altwegg, Kristin A.
    Li, Xiaonan
    Sareddy, Gangadhara R.
    Tekmal, Rajeshwar R.
    Vadlamudi, Ratna K.
    CANCER RESEARCH, 2020, 80 (16)
  • [10] SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance
    Liu, Zexuan
    Liu, Junhao
    Ebrahimi, Behnam
    Pratap, Uday P.
    He, Yi
    Altwegg, Kristin A.
    Tang, Weiwei
    Li, Xiaonan
    Lai, Zhao
    Chen, Yidong
    Shen, Liangfang
    Sareddy, Gangadhara R.
    Viswanadhapalli, Suryavathi
    Tekmal, Rajeshwar R.
    Rao, Manjeet K.
    Vadlamudi, Ratna K.
    BREAST CANCER RESEARCH, 2022, 24 (01)
12345